Literature DB >> 18591267

Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.

Martti Vaara1, John Fox, Günther Loidl, Osmo Siikanen, Juha Apajalahti, Frank Hansen, Niels Frimodt-Møller, Junya Nagai, Mikihisa Takano, Timo Vaara.   

Abstract

The lack of novel antibiotics against gram-negative bacteria has reinstated polymyxins as the drugs of last resort to treat serious infections caused by extremely multiresistant gram-negative organisms. However, polymyxins are nephrotoxic, and this feature may complicate therapy or even require its discontinuation. Like that of aminoglycosides, the nephrotoxicity of polymyxins might be related to the highly cationic nature of the molecule. Colistin and polymyxin B carry five positive charges. Here we show that novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. NAB739 has a cyclic peptide portion identical to that of polymyxin B, but in the linear portion of the peptide, it carries the threonyl-D-serinyl residue (no cationic charges) instead of the diaminobutyryl-threonyl-diaminobutyryl residue (two cationic charges). The MICs of NAB739 for 17 strains of Escherichia coli were identical, or very close, to those of polymyxin B. Furthermore, NAB739 was effective against other polymyxin-susceptible strains of Enterobacteriaceae and against Acinetobacter baumannii. At subinhibitory concentrations, it dramatically sensitized A. baumannii to low concentrations of antibiotics such as rifampin, clarithromycin, vancomycin, fusidic acid, and meropenem. NAB739 methanesulfonate was a prodrug analogous to colistin methanesulfonate. NAB740 was the most active derivative against Pseudomonas aeruginosa. NAB7061 (linear portion of the peptide, threonyl-aminobutyryl) lacked direct antibacterial activity but sensitized the targets to hydrophobic antibiotics by factors up to 2,000. The affinities of the NAB compounds for isolated rat kidney brush border membrane were significantly lower than that of polymyxin B.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591267      PMCID: PMC2533495          DOI: 10.1128/AAC.00405-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: studies on polymyxin B nonapeptide.

Authors:  H Tsubery; I Ofek; S Cohen; M Fridkin
Journal:  Biochemistry       Date:  2000-10-03       Impact factor: 3.162

Review 2.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

3.  Colistin: an antimicrobial for the 21st century?

Authors:  Andreas Stein; Didier Raoult
Journal:  Clin Infect Dis       Date:  2002-10-01       Impact factor: 9.079

Review 4.  Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.

Authors:  Alexandre Prehn Zavascki; Luciano Zubaran Goldani; Jian Li; Roger L Nation
Journal:  J Antimicrob Chemother       Date:  2007-09-17       Impact factor: 5.790

Review 5.  Introduction: the challenge of multiresistance.

Authors:  David M Livermore
Journal:  Int J Antimicrob Agents       Date:  2007-05       Impact factor: 5.283

Review 6.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

7.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

Authors:  Brad Spellberg; Robert Guidos; David Gilbert; John Bradley; Helen W Boucher; W Michael Scheld; John G Bartlett; John Edwards
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 8.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

9.  Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria.

Authors:  H Tsubery; I Ofek; S Cohen; M Fridkin
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

10.  Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more
  40 in total

1.  In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens.

Authors:  Michael Hornsey; Christopher Longshaw; Lynette Phee; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

2.  Identification of a polymyxin synthetase gene cluster of Paenibacillus polymyxa and heterologous expression of the gene in Bacillus subtilis.

Authors:  Soo-Keun Choi; Soo-Young Park; Rumi Kim; Seong-Bin Kim; Choong-Hwan Lee; Jihyun F Kim; Seung-Hwan Park
Journal:  J Bacteriol       Date:  2009-03-20       Impact factor: 3.490

3.  A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.

Authors:  Martti Vaara; Osmo Siikanen; Juha Apajalahti; John Fox; Niels Frimodt-Møller; Hui He; Anima Poudyal; Jian Li; Roger L Nation; Timo Vaara
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

Review 4.  Structure--activity relationships of polymyxin antibiotics.

Authors:  Tony Velkov; Philip E Thompson; Roger L Nation; Jian Li
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

5.  Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity.

Authors:  Elijah J Weber; Kevin A Lidberg; Lu Wang; Theo K Bammler; James W MacDonald; Mavis J Li; Michelle Redhair; William M Atkins; Cecilia Tran; Kelly M Hines; Josi Herron; Libin Xu; Maria Beatriz Monteiro; Susanne Ramm; Vishal Vaidya; Martti Vaara; Timo Vaara; Jonathan Himmelfarb; Edward J Kelly
Journal:  JCI Insight       Date:  2018-12-20

Review 6.  Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.

Authors:  Pamela Brown; Michael J Dawson
Journal:  J Antibiot (Tokyo)       Date:  2017-01-11       Impact factor: 2.649

Review 7.  SecA inhibitors as potential antimicrobial agents: differential actions on SecA-only and SecA-SecYEG protein-conducting channels.

Authors:  Jinshan Jin; Ying-Hsin Hsieh; Arpana S Chaudhary; Jianmei Cui; John E Houghton; Sen-Fang Sui; Binghe Wang; Phang C Tai
Journal:  FEMS Microbiol Lett       Date:  2018-08-01       Impact factor: 2.742

8.  Using Chemical Probes to Assess the Feasibility of Targeting SecA for Developing Antimicrobial Agents against Gram-Negative Bacteria.

Authors:  Jinshan Jin; Ying-Hsin Hsieh; Jianmei Cui; Krishna Damera; Chaofeng Dai; Arpana S Chaudhary; Hao Zhang; Hsiuchin Yang; Nannan Cao; Chun Jiang; Martti Vaara; Binghe Wang; Phang C Tai
Journal:  ChemMedChem       Date:  2016-10-18       Impact factor: 3.466

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes.

Authors:  Tony Velkov; Bo Yun; Elena K Schneider; Mohammad A K Azad; Olan Dolezal; Faye C Morris; Roger L Nation; Jiping Wang; Ke Chen; Heidi H Yu; Lv Wang; Philip E Thompson; Kade D Roberts; Jian Li
Journal:  ACS Infect Dis       Date:  2016-03-29       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.